UroGen Pharma
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $72,456 | $50,959 | $37,837 | $27,482 |
Gross Profit | 65,884 | 46,820 | 34,548 | 24,204 |
EBITDA | -3,757 | -19,003 | -22,188 | -25,768 |
EBIT | -3,835 | -19,655 | -22,867 | -26,407 |
Net Income | -14,351 | -23,574 | -26,364 | -33,347 |
Net Change In Cash | 72,456 | 50,959 | 37,837 | 27,482 |
Free Cash Flow | -33,066 | -45,370 | -38,342 | -42,357 |
Cash | 79,133 | 111,295 | 110,745 | 90,039 |
Basic Shares | 50,380 | 50,182 | 49,230 | 48,057 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $109,788 | $90,398 | $82,713 | $64,357 |
Gross Profit | 97,341 | 81,517 | 73,352 | 56,703 |
EBITDA | -135,660 | -95,353 | -60,352 | -76,214 |
EBIT | -138,071 | -95,682 | -62,057 | -78,031 |
Net Income | -153,494 | -126,874 | -102,244 | -109,783 |
Net Change In Cash | 109,788 | 90,398 | 82,713 | 64,357 |
Cost of Revenue | 10,635 | |||
Free Cash Flow | -162,733 | -97,061 | -76,570 | -87,813 |
Cash | 110,745 | 171,987 | 95,002 | 55,408 |
Basic Shares | 48,116 | 42,876 | 28,834 | 22,806 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.28 |
2026-03-31 | -$0.47 |
2025-12-31 | -$0.53 |
2025-09-30 | -$0.69 |